Trial Profile
Effects of simvastatin (20 mg/day) +/- niacin vs simvastatin (80 mg/day) on PCSK9 levels in dyslipidaemic patients with carotid atherosclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2012
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Simvastatin
- Indications Atherosclerosis; Dyslipidaemias
- Focus Pharmacodynamics
- 02 Dec 2012 New trial record
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.